Flowchart of included and excluded patients. by P.G.J. ter Horst (21743830)

Subjects:

Prevalence of low semen quality including 95% confidence interval (CI) for medication at the ATC 3 level. by P.G.J. ter Horst (21743830)

Subjects:

S1 Data - Medication, age and abstinence days associated with low semen quality: A cross-sectional study in more than 7000 men visiting the centre for reproductive medicine by P.G.J. ter Horst (21743830)

Subjects:

Univariable and multivariable analyses (age-adjusted), concerning a selection of medicaments p < 0.1 and n ≥ 10. by P.G.J. ter Horst (21743830)

Subjects:

Prevalence of low semen quality including 95% confidence interval (CI) for medication at the ATC 7 level. by P.G.J. ter Horst (21743830)

Subjects:

Characteristics of the study group. by P.G.J. ter Horst (21743830)

Subjects:

Univariable and multivariable analyses (age- and abstinence days-adjusted), concerning medicament(s) use and Low Semen Quality (LSQ). by P.G.J. ter Horst (21743830)

Subjects:

A. Proportion of men with Low Semen Quality (LSQ) including 95% confidence interval (CI) versus prevalence, overall and for men on medication(s) (M); B: Point estimates with 95% CI... by P.G.J. ter Horst (21743830)

Subjects:

Prevalence of low semen quality including 95% confidence interval (CI) for medication at the ATC 5 level. by P.G.J. ter Horst (21743830)

Subjects:

Univariable and multivariable analyses (age- and abstinence days-adjusted), concerning a selection of medicaments with n ≥ 10 medicament users and p < 0.1 by univariate analysis.... by P.G.J. ter Horst (21743830)

Subjects:

Magnification X2 of Fig 4A. by Huan W. Yang (19746645)

“…There were no significant changes in NF-κB signalling between vaccine and Dkp23 infection in PK-15 cells, except for moderate levels of differences in NF-κB target genes expression which might be a reflection of differences in intracellular bacterial load. …”

Flow diagram of participant selection. by Prajwal Paudel (7359209)

Subjects:

Bivariate association of characteristics of mothers (<34 weeks POG) who received and did not receive ACS. by Prajwal Paudel (7359209)

Subjects:

Supplementary file ACS. by Prajwal Paudel (7359209)

Subjects:

Multivariate analysis of the outcomes among the newborns who mothers receive or did not receive ACS. by Prajwal Paudel (7359209)

Subjects:

Bivariate analysis of morbidities among newborns whose mothers received or did not receive ACS. by Prajwal Paudel (7359209)

Subjects:

Multivariate analysis of the morbidities among the newborns who mothers receive or did not receive ACS. by Prajwal Paudel (7359209)

Subjects:

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment. by Kazuyoshi Ohkawa (836847)

Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during anastrozole treatment. by Kazuyoshi Ohkawa (836847)